Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Price:
41.975 USD
-2.97%
Market Closed
Updated:
May 29, 2024
Amphastar Pharmaceuticals Inc
Additional Paid In Capital
|
Amphastar Pharmaceuticals Inc
Additional Paid In Capital Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Additional Paid In Capital Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Additional Paid In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
|
Additional Paid In Capital
$476.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Additional Paid In Capital
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Additional Paid In Capital
$45.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
85%
|
CAGR 10-Years
41%
|
|
|
Pfizer Inc
NYSE:PFE
|
Additional Paid In Capital
$93B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Additional Paid In Capital
$44.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Additional Paid In Capital
$7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
See Also
What is Amphastar Pharmaceuticals Inc's Additional Paid In Capital?
Additional Paid In Capital
476.1m
USD
476.1m
USD
Based on the financial report for Mar 31, 2024, Amphastar Pharmaceuticals Inc's Additional Paid In Capital amounts to 476.1m USD.
What is Amphastar Pharmaceuticals Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
10%
10%
Over the last year, the Additional Paid In Capital growth was 4%. The average annual Additional Paid In Capital growth rates for Amphastar Pharmaceuticals Inc have been 5% over the past three years , 6% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
